Monthly Prescribing Reference10h
FDA Approves First Generic Version of Victoza for Type 2 Diabetes
The ongoing shortage of liraglutide injection and other GLP-1 medications prompted the FDA to prioritize the generic drug applications for these medications in order to improve patient access.
Monthly Prescribing Reference9h
Fish Oil Supplementation Cuts Measure of Prostate Cancer Progression
(HealthDay News) — A high omega-3, low omega-6 diet with fish oil supplementation for one year results in a significant reduction of a marker of prostate cancer progression among men enrolled in ...
Monthly Prescribing Reference12h
FDA Denies Approval of Zynquista for Type 1 Diabetes and CKD
The resubmitted NDA for sotagliflozin for adults with T1D and CKD included post hoc analyses from the TANDEM clinical development program and post hoc analysis from the SCORED trial.
Monthly Prescribing Reference11h
Gemtesa Approved for Men With OAB Symptoms Receiving BPH Treatment
The approval was based on data from the randomized, double-blind, placebo-controlled phase 3 URO-901-3005 trial.
Monthly Prescribing Reference8h
Higher Daily Step Count Linked to Lower Risk for Depression
(HealthDay News) — Higher daily step counts are associated with fewer depressive symptoms in adults, according to a systematic review and meta-analysis published online online December 16 in JAMA ...
Monthly Prescribing Reference10h
β-Catenin Antagonist Designated Orphan Drug for Familial Adenomatous Polyposis
The Orphan Drug designation is based on data from the dose escalation phase of the open-label phase 1/2 study.